RT Journal Article
SR Electronic
T1 Interpreting the COMET trial
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 1081
OP 1087
VO 70
IS 12
A1 Tang, W.H. Wilson
A1 Militello, Michael
A1 Francis, Gary S.
YR 2003
UL http://www.ccjm.org/content/70/12/1081.abstract
AB The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7–13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate. Whether the target doses used were equivalent (carvedilol 25 mg twice daily vs metoprolol tartrate 50 mg twice daily) has been debated, but the COMET trial shows that drugs in the same class do not necessarily have the same effects. Given the overwhelming evidence of the benefit of carvedilol, metoprolol succinate, and bisoprolol in patients with heart failure, we should all strive to increase the use of these drugs in appropriate doses.